Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy is often unpredictable. Treatment of NP currently involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid analgesics. Treatment plans are also typically individualized and empirically based. This report will explore the U.S. NP treatment landscape with a focus on current medical practice in this population.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 51 U.S. PCPs and 51 U.S. neurologists fielded in July 2019
Key companies: Grünenthal / Averitas Pharma , Janssen, Assertio Therapeutics, Pfizer, Arbor Pharmaceuticals
Key drugs: Lyrica, Lyrica CR, duloxetine, gabapentin, Nucynta ER, Gralise, Horizant, Qutenza, 5% lidocaine patch